News
RDHL
0.8786
+2.15%
0.0185
RedHill Biopharma Sets July 28, 2026 AGM to Vote on Board, Auditor and Chairman-CEO Role
TipRanks · 1d ago
RedHill Biopharma Closes $6 Million Private Placement to Fund Potential Acquisition
TipRanks · 4d ago
RedHill Biopharma Raises $6 Million in June 2026 Private Placement of ADSs and Warrants
TipRanks · 4d ago
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
PR Newswire · 4d ago
RedHill Biopharma Sets July 28, 2026 Shareholder Meeting to Vote on Board, CEO-Chairman Role
TipRanks · 4d ago
Weekly Report: what happened at RDHL last week (0615-0619)?
Weekly Report · 4d ago
RedHill Biopharma Secures Up to $19.4 Million in Private Placement to Fund Pipeline and Potential Acquisition
TipRanks · 06/18 12:26
RedHill Biopharma Commences ~$6M Offering Of American Depositary Shares, Series A-2 Warrants At $0.70/ADS
Benzinga · 06/18 12:05
RedHill Biopharma Announces Up To $19.4 Million Private Placement
PR Newswire · 06/18 12:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/16 21:06
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
TipRanks · 06/16 12:00
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 06/15 21:05
Weekly Report: what happened at RDHL last week (0608-0612)?
Weekly Report · 06/15 10:09
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 06/12 12:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 06/11 21:05
RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst
TipRanks · 06/10 14:00
RedHill: FDA Grants Rare Pediatric Disease Designation To Opaganib
NASDAQ · 06/09 12:08
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 06/09 12:05
RedHill Biopharma’s opaganib granted FDA Rare Pediatric Disease designation
TipRanks · 06/09 11:06
Redhill Biopharma Announces FDA Rare Pediatric Disease Designation For Opaganib For The Treatment Of Neuroblastoma
Benzinga · 06/09 11:06
More
Webull provides a variety of real-time RDHL stock news. You can receive the latest news about Redhill Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.